Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLL018 in Moderate to Severe Ulcerative Colitis
NCT05121402Phase 2Withdrawn
- Sponsor
- TLL Pharmaceutical, LLC
- Start
- Dec 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of girocitinib in ulcerative colitis (UC), sponsored by TLL Pharmaceutical, LLC. Planned start Dec 2022; status: withdrawn.
02
Drugs
girocitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05121402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05121402.